Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orexigen Therapeutics Inc.

Latest From Orexigen Therapeutics Inc.

10 Drug Launch Flops Of The Decade

The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.

Launches Business Strategies

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B

Private Company Edition: Morphic raises $80m to take its first two integrin inhibitors into the clinic for fibrosis and inflammatory bowel disease. Also, Hillhouse has a new $10.6bn private equity fund for health care and other investments, and Atreca closes a $125m Series C.

Financing Business Strategies

CAMELLIA Adds To Belviq’s CV Confidence But ‘Caution’ Still Needed

Full results from a large cardiovascular outcomes study with Belviq show the Eisai/Arena obesity drug was not associated with higher such risk versus placebo, but neither did it show benefits in reducing major CV events, leaving uncertainty over its increased uptake amid lingering issues around diabetes and valvulopathy risks.

Clinical Trials Safety
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Orexigen Therapeutics Inc.
  • Senior Management
  • Michael Narachi, Pres. & CEO
    Jason Keyes, SVP, CFO
    Peter Flynn, SVP & Head, Dev., Regulatory Affairs & Safety
  • Contact Info
  • Orexigen Therapeutics Inc.
    Phone: (858) 875-8600
    3344 N. Torrey Pines Ct., Ste. 200
    La Jolla, CA 92037